<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648698</url>
  </required_header>
  <id_info>
    <org_study_id>FuXingH</org_study_id>
    <nct_id>NCT02648698</nct_id>
  </id_info>
  <brief_title>RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis</brief_title>
  <official_title>A Prospective, Randomized, Placebo-controlled Trial on the Effect of Antibiotic Therapy on Endometrial Response in Women With Chronic Endometritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fu Xing Hospital, Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fu Xing Hospital, Capital Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      82 cases with a diagnosis of chronic endometritis, confirmed by the presence of plasma cells
      in endometrial biopsy sample identified by immunohistochemical staining using CD138 antibody,
      will be recruited. The subjects will be randomly divided into two groups, the experimental
      group will be given antibiotic (Augmentin) treatment, the control group will be given
      placebo. A repeat endometrial biopsy sample will be obtained one month after completion of
      the antibiotic therapy to assess the response to treatment. The cure rate will be compared
      between the two groups
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be carried out at the Hysteroscopy centre of the Fuxing Hospital, Beijing,
      China. A total of 82 women with chronic endometritis who fulfilled the following inclusion
      criteria will be recruited:

        1. Pre-menopausal

        2. Agreed to have repeat hysteroscopy and a second endometrial biopsy ~4 weeks after the
           first hysteroscopy and endometrial biopsy

        3. No evidence of hyperplasia or cancer in the initial endometrial biopsy

      Exclusion Criteria:

        1. steroid hormone therapy within the preceding one month of recruitment

        2. Allergy to antibiotic

        3. Concurrent infection which require additional courses of antibiotic therapy before the
           second endometrial biopsy specimen.

      Power calculation: assuming that the spontaneous CD138 conversion (from +ve to -ve) rate is
      25% and that the antibiotic therapy results in 60% conversion rate, the total number of
      subjects required in each arm of the RCT will be 37, accepting a Type I error of 0.05 and a
      Type II error of 0.1. Assuming a drop-out rate of 10%, 41 subjects will need to be recruited
      into each arm. Hence, a total of 82 subjects who fulfilled the inclusion criteria will be
      required.

      Recruitment: Women will be recruited form the day case hysteroscopy unit of the Hysteroscopy
      center, Fuxing Hospital, Beijing, China. The Hysteroscopy center currently carries out ~600
      day case hysteroscopy per month. In all cases, endometrial biopsy specimen will be obtained
      at the time of hysteroscopy for histological evaluation. Since 2013, all endometrial
      specimens have been routinely examined with the used of CD138 antibody to establish if there
      is evidence of chronic endometritis, in addition to routine histopathological examination.
      Previous audit showed that ~15% of subjects had positive staining for CD138 cells. In
      addition, it is estimated that about 1/5 of subjects undergoing hysteroscopy and biopsy will
      fulfill the inclusion criteria. Assuming a successful recruitment rate of 75% among those who
      are eligible, the total number of subjects to be screened will be 3,650 in order to
      successfully recruit 82 subjects. Given that we carry out ~600 hysteroscopy per month, the
      recruitment will take ~6-9 months.

      Randomization: computer generated Antibiotic therapy: Staff Pharmacist will dispense
      medication; placebo will consist of vitamin C tablet Consent: written informed consent will
      be obtained Repeat endometrial biopsy &amp; histological evaluation: The repeat endometrial
      biopsy will be performed after completion of the the antibiotic therapy. Immunohistochemical
      study using CD138 antibody will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The negative rate of the two groups in CD138 positive patients with and without treatment</measure>
    <time_frame>six months</time_frame>
    <description>patients with positive of CD138 treated by antibiotic were followed for how many patients transform negative in CD138</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Live birth rate of patients with CD138 positive and negative</measure>
    <time_frame>one year</time_frame>
    <description>To follow up the live birth rate in patients with CD138 positive and negative after antibiotic treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Chronic Endometritis</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The positive patients of CD138 were randomly divided into two groups, patients in group 1 treated by antibiotic .Group 2 treated by vitamin C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The positive patients of CD138 were randomly divided into two groups, Patient in Group 2 treated by vitamin C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antibiotics</intervention_name>
    <description>Levofloxacin Tab and Tinidazole Tab are combined in the experimental group</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>KeLeBiTuo (Levofloxacin Tab）and Tixiaozuo Pian （Tinidazole Tab)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Vitamin c is used as a placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pre-menopausal

          2. Agreed to have repeat hysteroscopy and a second endometrial biopsy ~4 weeks after the
             first hysteroscopy and endometrial biopsy

          3. No evidence of hyperplasia or cancer in the initial endometrial biopsy

        Exclusion Criteria:

          1. Steroid hormone therapy within the preceding one month of recruitment

          2. Allergy to antibiotic

          3. Concurrent infection which require additional courses of antibiotic therapy before the
             second endometrial biopsy specimen.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongmei Song, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>FuXing Hospital,Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enlan Xia, Master</last_name>
    <role>Study Director</role>
    <affiliation>FuXing Hospital,Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tinchiu Li, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>FuXing Hospital,Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoxia Peng, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongmei Song, Master</last_name>
    <phone>+0086 13651294056</phone>
    <email>echosdm@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shanshan Zheng</last_name>
    <phone>00861088062032</phone>
    <email>fxyykjk@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FuXing Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongmei Song, MD</last_name>
      <phone>008613651294056</phone>
      <email>echosdm@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Qin Zhong</last_name>
      <phone>00861088062944</phone>
      <email>fxyykjk@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tinchiu Li, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enlan Xia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26207958</url>
    <description>2015</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24462055</url>
    <description>2014</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24177713</url>
    <description>2013 Oct 31</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21030015</url>
    <description>2011 Mar</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Routine+syndecan-1+immunohistochemistry+aids+in+the+diagnosis+of+chronic+endometritis</url>
    <description>2004 Sep</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23440678</url>
    <description>2012 Jul</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Immunohistochemistrical+and+clinicopathological+characterization+of+chronic+endometritis</url>
    <description>2011 Jul 12</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25385744</url>
    <description>2015 Feb</description>
  </link>
  <reference>
    <citation>McQueen DB, Bernardi LA, Stephenson MD. Chronic endometritis in women with recurrent early pregnancy loss and/or fetal demise. Fertil Steril. 2014 Apr;101(4):1026-30. doi: 10.1016/j.fertnstert.2013.12.031. Epub 2014 Jan 23.</citation>
    <PMID>24462055</PMID>
  </reference>
  <reference>
    <citation>Cicinelli E, Matteo M, Tinelli R, Pinto V, Marinaccio M, Indraccolo U, De Ziegler D, Resta L. Chronic endometritis due to common bacteria is prevalent in women with recurrent miscarriage as confirmed by improved pregnancy outcome after antibiotic treatment. Reprod Sci. 2014 May;21(5):640-7. doi: 10.1177/1933719113508817. Epub 2013 Oct 31.</citation>
    <PMID>24177713</PMID>
  </reference>
  <reference>
    <citation>Kitaya K. Prevalence of chronic endometritis in recurrent miscarriages. Fertil Steril. 2011 Mar 1;95(3):1156-8. doi: 10.1016/j.fertnstert.2010.09.061. Epub 2010 Oct 28.</citation>
    <PMID>21030015</PMID>
  </reference>
  <reference>
    <citation>Bayer-Garner IB, Nickell JA, Korourian S. Routine syndecan-1 immunohistochemistry aids in the diagnosis of chronic endometritis. Arch Pathol Lab Med. 2004 Sep;128(9):1000-3.</citation>
    <PMID>15335255</PMID>
  </reference>
  <reference>
    <citation>Kannar V, Lingaiah HK, Sunita V. Evaluation of endometrium for chronic endometritis by using syndecan-1 in abnormal uterine bleeding. J Lab Physicians. 2012 Jul;4(2):69-73. doi: 10.4103/0974-2727.105584.</citation>
    <PMID>23440678</PMID>
  </reference>
  <reference>
    <citation>Kitaya K, Yasuo T. Immunohistochemistrical and clinicopathological characterization of chronic endometritis. Am J Reprod Immunol. 2011 Nov;66(5):410-5. doi: 10.1111/j.1600-0897.2011.01051.x. Epub 2011 Jul 12.</citation>
    <PMID>21749546</PMID>
  </reference>
  <reference>
    <citation>Cicinelli E, Matteo M, Tinelli R, Lepera A, Alfonso R, Indraccolo U, Marrocchella S, Greco P, Resta L. Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy. Hum Reprod. 2015 Feb;30(2):323-30. doi: 10.1093/humrep/deu292. Epub 2014 Nov 10.</citation>
    <PMID>25385744</PMID>
  </reference>
  <results_reference>
    <citation>McQueen DB, Perfetto CO, Hazard FK, Lathi RB. Pregnancy outcomes in women with chronic endometritis and recurrent pregnancy loss. Fertil Steril. 2015 Oct;104(4):927-931. doi: 10.1016/j.fertnstert.2015.06.044. Epub 2015 Jul 21.</citation>
    <PMID>26207958</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fu Xing Hospital, Capital Medical University</investigator_affiliation>
    <investigator_full_name>Song Dongmei</investigator_full_name>
    <investigator_title>Hysteroscopy Center</investigator_title>
  </responsible_party>
  <keyword>chronic endometritis</keyword>
  <keyword>CD138</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

